ArticleJournal of diabetes investigation2026
Frequency of islet autoantibody seropositivity among adults with newly diagnosed type 2 diabetes in the Kazakh population: A cross-sectional study.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
AIMS/
introductionType 2 diabetes mellitus (T2DM) is a heterogeneous condition, and a proportion of patients show autoimmune features consistent with latent autoimmune diabetes in adults (LADA). This study assessed the prevalence of islet autoantibodies in newly diagnosed T2DM patients of Kazakh ethnicity. MATERIALS AND
methodsA cross-sectional study was conducted in 240 patients (30-75 years) with newly diagnosed T2DM in the Aktobe region, Kazakhstan (May 2024-January 2025). Clinical data, HbA1c, and fasting C-peptide were measured. Autoantibodies (GADA, ZnT8A, IA-2A, ICA-ELISA) were determined by ELISA.
resultsOverall, 25.8% of patients were positive for at least one islet autoantibody. ZnT8A (13.3%) and GADA (5.8%) were the most frequent, while IA-2A and ICA-ELISA were rare (0.8% each). Double positivity was observed in 4.6% of patients, and triple positivity in 0.4%. GADA was associated with lower BMI (kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.